On July 23, Hims & Hers Health Inc. rose 6.69% in regular trading, reaching $33.3923 per share with turnover of approximately $202 million.

On the news front, the company actively urged the U.S. Food and Drug Administration (FDA) during a panel meeting to expand accessibility to specific peptide drugs. The market responded positively to this development. If the FDA ultimately lowers related access barriers, it could broaden the prescription drug coverage on the company's telehealth platform and create incremental growth opportunities for its GLP-1 weight management business.

This move aligns with Hims & Hers' broader strategic push into weight management services. The company recently launched generic semaglutide for eligible customers in Canada and completed its acquisition of Eucalyptus in early June, expanding its consumer health platform across Australia, Canada, Germany, and other international markets. Additionally, BofA Securities raised its price target on the stock to $36 from $25 in early July, reflecting growing analyst confidence in the company's growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)